Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ
Yau-Sheng Tsai, … , Jason K. Kim, Nobuyo Maeda
Yau-Sheng Tsai, … , Jason K. Kim, Nobuyo Maeda
Published July 15, 2004
Citation Information: J Clin Invest. 2004;114(2):240-249. https://doi.org/10.1172/JCI20964.
View: Text | PDF
Article Cardiology Article has an altmetric score of 3

Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ

  • Text
  • PDF
Abstract

Peroxisome proliferator–activated receptor γ (PPARγ), the molecular target of a class of insulin sensitizers, regulates adipocyte differentiation and lipid metabolism. A dominant negative P467L mutation in the ligand-binding domain of PPARγ in humans is associated with severe insulin resistance and hypertension. Homozygous mice with the equivalent P465L mutation die in utero. Heterozygous mice grow normally and have normal total adipose tissue weight. However, they have reduced interscapular brown adipose tissue and intra-abdominal fat mass, and increased extra-abdominal subcutaneous fat, compared with wild-type mice. They have normal plasma glucose levels and insulin sensitivity, and increased glucose tolerance. However, during high-fat feeding, their plasma insulin levels are mildly elevated in association with a significant increase in pancreatic islet mass. They are hypertensive, and expression of the angiotensinogen gene is increased in their subcutaneous adipose tissues. The effects of P465L on blood pressure, fat distribution, and insulin sensitivity are the same in both male and female mice regardless of diet and age. Thus the P465L mutation alone is sufficient to cause abnormal fat distribution and hypertension but not insulin resistance in mice. These results provide genetic evidence for a critical role for PPARγ in blood pressure regulation that is not dependent on altered insulin sensitivity.

Authors

Yau-Sheng Tsai, Hyo-Jeong Kim, Nobuyuki Takahashi, Hyung-Suk Kim, John R. Hagaman, Jason K. Kim, Nobuyo Maeda

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2004 Total
Citations: 1 1 1 3 3 2 4 2 1 4 1 3 3 7 4 9 7 5 8 4 1 74
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (74)

Title and authors Publication Year
PVAT Adipocyte: Energizing, Modulating, and Structuring Vascular Function During Normotensive and Hypertensive States
Rendon CJ, Watts SW, Contreras GA
American journal of physiology. Heart and circulatory physiology 2025
Impaired Remodeling of White Adipose Tissue in Obesity and Aging: From Defective Adipogenesis to Adipose Organ Dysfunction.
Iacobini C, Vitale M, Haxhi J, Menini S, Pugliese G
Cells 2024
Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPARγ Expression
Chang CS, Yu SS, Ho LC, Chao SH, Chou TY, Shao AN, Kao LZ, Chang CY, Chen YH, Wu MS, Tsai PJ, Maeda N, Tsai YS
International journal of molecular sciences 2023
Not Enough Fat: Mouse Models of Inherited Lipodystrophy
S Lay, J Magré, X Prieur
Frontiers in Endocrinology 2022
Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants
Vasandani C, Li X, Sekizkardes H, Brown RJ, Garg A
Journal of the Endocrine Society 2022
Peroxisome proliferator-activated receptor-γ as the gatekeeper of tight junction in Clostridioides difficile infection
Lai YH, Wu TC, Tsai BY, Hung YP, Lin HJ, Tsai YS, Ko WC, Tsai PJ
Frontiers in microbiology 2022
Role of the Peroxisome Proliferator Activated Receptors in Hypertension
S Fang, MC Livergood, P Nakagawa, J Wu, CD Sigmund
Circulation research 2021
PPARγ activation improves the microenvironment of perivascular adipose tissue and attenuates aortic stiffening in obesity
JY Chen, YP Wu, CY Li, HF Jheng, LZ Kao, CC Yang, SY Leu, IC Lien, WT Weng, HC Tai, YW Chiou, MJ Tang, PJ Tsai, YS Tsai
Journal of Biomedical Science 2021
Inhibitory effect of PPARγ on NLRP3 inflammasome activation
CC Yang, CH Wu, TC Lin, YN Cheng, CS Chang, KT Lee, PJ Tsai, YS Tsai
Theranostics 2021
PPARγ and RhoBTB1 in hypertension:
S Fang, CD Sigmund
Current Opinion in Nephrology and Hypertension 2020
Loss of EGR-1 uncouples compensatory responses of pancreatic β cells
SY Leu, LH Kuo, WT Weng, IC Lien, CC Yang, TT Hsieh, YN Cheng, PH Chien, LC Ho, SH Chen, YS Shan, YW Chen, PC Chen, PJ Tsai, JM Sung, YS Tsai
Theranostics 2020
What lipodystrophies teach us about the metabolic syndrome
Jake P. Mann, David Savage
Journal of Clinical Investigation 2019
The Protective Role of Peroxisome Proliferator-Activated Receptor-Gamma in Seizure and Neuronal Excitotoxicity
TY Hung, FL Chu, DC Wu, SN Wu, CW Huang
Molecular Neurobiology 2019
Endothelial PPARγ Is Crucial for Averting Age-Related Vascular Dysfunction by Stalling Oxidative Stress and ROCK
S Uddin, T Kabir, Jakaria, AA Mamun, K Niaz, S Amran, GE Barreto, GhulamAshraf
Neurotoxicity Research 2019
Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants
H Sekizkardes, E Cochran, N Malandrino, A Garg, RJ Brown
The Journal of clinical endocrinology and metabolism 2019
Endothelial PPARγ (Peroxisome Proliferator–Activated Receptor-γ) Is Essential for Preventing Endothelial Dysfunction With Aging
TM Silva, Y Li, DA Kinzenbaw, CD Sigmund, FM Faraci
Hypertension 2018
Serum PPARγ level and PPARγ gene polymorphism as well as severity and prognosis of brain injury in patients with arteriosclotic cerebral infarction
W Wei, X Chen, X Lin, F Shan, S Lin, Q Shen, L Zhang
Experimental and therapeutic medicine 2018
Lactobacillus gasseri attenuates allergic airway inflammation through PPARγ activation in dendritic cells
MH Hsieh, RL Jan, LS Wu, PC Chen, HF Kao, WS Kuo, JY Wang
Journal of Molecular Medicine 2017
Adipocyte (Pro)Renin-Receptor Deficiency Induces Lipodystrophy, Liver Steatosis and Increases Blood Pressure in Male MiceNovelty and Significance
CH Wu, S Mohammadmoradi, J Thompson, W Su, M Gong, G Nguyen, F Yiannikouris
Hypertension 2016
Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?
A Pap, I Cuaranta-Monroy, M Peloquin, L Nagy
International journal of molecular sciences 2016
Peroxisome proliferator activating receptor-γ and the podocyte
C Platt, RJ Coward
Nephrology Dialysis Transplantation 2016
Effect of selective expression of dominant-negative PPARγ in pro-opiomelanocortin neurons on the control of energy balance
M Stump, DF Guo, KT Lu, M Mukohda, X Liu, K Rahmouni, CD Sigmund
Physiological genomics 2016
PPARγ Regulation in Hypertension and Metabolic Syndrome
M Stump, M Mukohda, C Hu, CD Sigmund
Current Hypertension Reports 2015
Diuretics Prevent Thiazolidinedione-Induced Cardiac Hypertrophy without Compromising Insulin-Sensitizing Effects in Mice
CS Chang, PJ Tsai, JM Sung, JY Chen, LC Ho, K Pandya, N Maeda, YS Tsai
The American Journal of Pathology 2014
Role of Vascular Smooth Muscle PPARγ in Regulating AT1 Receptor Signaling and Angiotensin II-Dependent Hypertension
MA Carrillo-Sepulveda, HL Keen, DR Davis, JL Grobe, CD Sigmund
PloS one 2014
Role of Peroxisome Proliferator-Activated Receptor-  in Vascular Muscle in the Cerebral Circulation
TM de Silva, ML Modrick, P Ketsawatsomkron, C Lynch, Y Chu, CJ Pelham, CD Sigmund, FM Faraci
Hypertension 2014
Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle
CJ Pelham, HL Keen, SR Lentz, CD Sigmund
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2013
PPARγ: no SirT, no service
FW Quelle, CD Sigmund
Circulation research 2013
A Clinical Link Between Peroxisome Proliferator-Activated Receptor γ and the Renin–Angiotensin System
CD Sigmund
Arteriosclerosis, thrombosis, and vascular biology 2013
Cullin-3 Regulates Vascular Smooth Muscle Function and Arterial Blood Pressure via PPARγ and RhoA/Rho-Kinase
CJ Pelham, P Ketsawatsomkron, S Groh, JL Grobe, WJ de Lange, SR Ibeawuchi, HL Keen, ET Weatherford, FM Faraci, CD Sigmund
Cell Metabolism 2012
Consequences of stopping and restarting leptin in an adolescent with lipodystrophy
F Kamran, KI Rother, E Cochran, ES Zadeh, P Gorden, RJ Brown
Hormone Research in Pædiatrics 2012
Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) and Neurodegenerative Disorders
YC Chen, JS Wu, HD Tsai, CY Huang, JJ Chen, GY Sun, TN Lin
Molecular Neurobiology 2012
Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesity
D Zhao, BH McCully, VL Brooks
The Journal of pharmacology and experimental therapeutics 2012
Peroxisome proliferator-activated receptor-γ protects against vascular aging
ML Modrick, DA Kinzenbaw, Y Chu, CD Sigmund, FM Faraci
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2012
Pro- and Antiatherogenic Effects of a Dominant-Negative P465L Mutation of Peroxisome Proliferator–Activated Receptor-γ in Apolipoprotein E–Null Mic
AA Pendse, LA Johnson, HS Kim, M McNair, CT Nipp, C Wilhelm, N Maeda
Arteriosclerosis, thrombosis, and vascular biology 2012
PPARγ Regulates Resistance Vessel Tone Through a Mechanism Involving RGS5-Mediated Control of Protein Kinase C and BKCa Channel Activity
P Ketsawatsomkron, RA Lorca, HL Keen, ET Weatherford, X Liu, CJ Pelham, JL Grobe, FM Faraci, SK England, CD Sigmund
Circulation research 2012
Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-γ
SL Chan, MJ Cipolla
The FASEB Journal 2011
Protecting against vascular disease in brain
FM Faraci
American journal of physiology. Heart and circulatory physiology 2011
Carbon-nanoparticle-triggered acute lung inflammation and its resolution are not altered in PPARγ-defective (P465L) mice
AA Götz, A Vidal-Puig, HG Rödel, MH de Angelis, T Stoeger
Particle and Fibre Toxicology 2011
PPARγ Agonist Beyond Glucose Lowering Effect
A Sugawara, A Uruno, M Kudo, K Matsuda, CW Yang, S Ito
The Korean Journal of Internal Medicine 2011
Inhibitor of DNA binding 4 (ID4) regulation of adipocyte differentiation and adipose tissue formation in mice
JM Murad, CS Place, C Ran, SK Hekmatyar, NP Watson, RA Kauppinen, MA Israel
The Journal of biological chemistry 2010
Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease
S Azhar
Future Cardiology 2010
Anti-apoptotic Actions of PPAR-γ Against Ischemic Stroke
WH Fong, HD Tsai, YC Chen, JS Wu, TN Lin
Molecular Neurobiology 2010
PPARs in the Renal Regulation of Systemic Blood Pressure
T Roszer, M Ricote
PPAR Research 2010
Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature?
P Ketsawatsomkron, CJ Pelham, S Groh, HL Keen, FM Faraci, CD Sigmund
The Journal of biological chemistry 2010
Pparg-P465L Mutation Worsens Hyperglycemia in Ins2-Akita Female Mice via Adipose-Specific Insulin Resistance and Storage Dysfunction
AA Pendse, LA Johnson, YS Tsai, N Maeda
Diabetes 2010
Pioglitazone-Induced Reductions in Atherosclerosis Occur via Smooth Muscle Cell–Specific Interaction With PPARγ
V Subramanian, J Golledge, T Ijaz, D Bruemmer, A Daugherty
Circulation research 2010
Endothelial and Vascular Muscle PPARγ in Arterial Pressure Regulation: Lessons From Genetic Interference and Deficiency
CD Sigmund
Hypertension 2010
Bioinformatic Analysis of Gene Sets Regulated by Ligand-Activated and Dominant-Negative Peroxisome Proliferator–Activated Receptor γ in Mouse Aorta
HL Keen, CM Halabi, AM Beyer, WJ de Lange, X Liu, N Maeda, FM Faraci, TL Casavant, CD Sigmund
Arteriosclerosis, thrombosis, and vascular biology 2010
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009
Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice
A Kis, C Murdoch, M Zhang, A Siva, S Rodriguez-Cuenca, S Carobbio, A Lukasik, M Blount, S O'Rahilly, SL Gray, AM Shah, A Vidal-Puig
European Journal of Heart Failure 2009
Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure
YS Tsai, L Xu, O Smithies, N Maeda
Proceedings of the National Academy of Sciences 2009
The role of peroxisome proliferator-activated receptor γ in blood pressure regulation
M Hamblin, L Chang, J Zhang, YE Chen
Current Hypertension Reports 2009
Decreased PPARγ Expression Compromises Perigonadal-Specific Fat Deposition and Insulin Sensitivity
YS Tsai, PJ Tsai, MJ Jiang, TY Chou, A Pendse, HS Kim, N Maeda
Molecular Endocrinology 2009
Ligand-Activated Peroxisome Proliferator–Activated Receptor-γ Protects Against Ischemic Cerebral Infarction and Neuronal Apoptosis by 14-3-3ε Upregulation
JS Wu, WM Cheung, YS Tsai, YT Chen, WH Fong, HD Tsai, YC Chen, JY Liou, SK Shyue, JJ Chen, YE Chen, N Maeda, KK Wu, TN Lin
Circulation 2009
Dominant-Negative Loss of PPARγ Function Enhances Smooth Muscle Cell Proliferation, Migration, and Vascular Remodeling
D Meredith, M Panchatcharam, S Miriyala, YS Tsai, AJ Morris, N Maeda, GA Stouffer, SS Smyth
Arteriosclerosis, thrombosis, and vascular biology 2009
Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling
AM Beyer, GL Baumbach, CM Halabi, ML Modrick, CM Lynch, TD Gerhold, SM Ghoneim, WJ de Lange, HL Keen, YS Tsai, N Maeda, CD Sigmund, FM Faraci
Hypertension 2008
Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet
AM Beyer, WJ de Lange, CM Halabi, ML Modrick, HL Keen, FM Faraci, CD Sigmund
Circulation research 2008
PPAR-γ in the Cardiovascular System
SZ Duan, CY Ivashchenko, MG Usher, RM Mortensen
PPAR Research 2008
Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension
CM Halabi, AM Beyer, WJ de Lange, HL Keen, GL Baumbach, FM Faraci, CD Sigmund
Cell Metabolism 2008
PPARγ and its ligands: therapeutic implications in cardiovascular disease
L Villacorta, FJ Schopfer, J Zhang, BA Freeman, YE Chen
Clinical Science 2008
Hypotension, lipodystrophy, and insulin resistance in generalized PPAR-gamma deficient mice rescued from embryonic lethality
Sheng Zhong Duan, Christine Y. Ivashchenko, Steven E. Whitesall, Louis G. D'Alecy, Damon C. Duquaine, Frank C. Brosius III, Frank J. Gonzalez, Charles Vinson, Melissa A. Pierre, David S. Milstone, and Richard M. Mortensen
Journal of Clinical Investigation 2007
Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin
N Takahashi, F Li, K Hua, J Deng, CH Wang, RR Bowers, TJ Bartness, HS Kim, JB Harp
Cell Metabolism 2007
'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies
M Gurnell
PPAR Research 2007
Genetic manipulations of PPARs: effects on obesity and metabolic disease
Y Barak, S Kim
PPAR Research 2007
PPARgamma in human and mouse physiology
S Heikkinen, J Auwerx, CA Argmann
Biochimica et Biophysica Acta 2007
Mouse Models of Lipodystrophy Key reagents for the understanding of the metabolic syndrome
IW Asterholm, N Halberg, PE Scherer
Drug discovery today. Disease models 2007
Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk
Y Wan, A Saghatelian, LW Chong, CL Zhang, BF Cravatt, RM Evans
Genes & development 2007
Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation
JM Guettier, JY Park, EK Cochran, C Poitou, A Basdevant, M Meier, K Clément, J Magré, P Gorden
Clinical Endocrinology 2007
PPARγ and human metabolic disease
RK Semple, VK Chatterjee, S O'Rahilly
Journal of Clinical Investigation 2006
Quantitative trait loci for individual adipose depot weights in C57BL/6ByJ x 129P3/J F2 mice
DR Reed, AH McDaniel, X Li, MG Tordoff, AA Bachmanov
Mammalian Genome 2006
The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system
S Kim, M Soltani-Bejnood, A Quignard-Boulange, F Massiera, M Teboul, G Ailhaud, JH Kim, N Moustaid-Moussa, BH Voy
Journal of biomedicine & biotechnology 2006
Peroxisomal proliferator activated receptor-γ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3)
GA Francis, G Li, R Casey, J Wang, H Cao, T Leff, RA Hegele
BMC Medical Genetics 2006
Unbuckling lipodystrophy from insulin resistance and hypertension.
Hegele RA, Leff T
Journal of Clinical Investigation 2004

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
6 readers on Mendeley
See more details